Stocks jumped in early trading Thursday as investors shrugged off fears of higher interest rates. The 10-year yield pulled back from a 4-year high, which caused some investors to push the sell button towards the end of the trading day Wednesday. John Petrides, Managing Director & Portfolio Manager at Point View Wealth Management was with us to give us the good and the bad of the current state of the markets. Investors aren't too complacent. He said they were in 2017. Volatility over the last 3 weeks has brought everyone back to a "normalized state," according to Petrides. He believes the market is pricing in the possibility of a fourth rate hike, adding to the volatility. Even in a rising rate environment, Petrides thinks stocks can still rise. He said the markets have been propped up by the Fed, but now stocks will have to growth through strong earnings and demand for their goods and services.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More